Magic Pill

Johann Hari, a journalist, combines memoir, investigative journalism, and science writing to examine the new generation of weight-loss drugs, including Ozempic and Wegovy. Drawing on interviews with over 100 experts and his own experience taking the drugs, he weighs their health benefits against their risks and asks what their rise reveals about modern society's relationship with food.

Hari begins at a Hollywood party in winter 2022, where he notices that everyone has become strikingly gaunt while he has gained 20 pounds. A friend reveals the secret: a new injectable weight-loss drug. The discovery stirs immediate conflict. Hari has a lifelong relationship with junk food, and his family history is alarming: his grandfather died of a heart attack at 44, his uncle in his sixties, and his father required a quadruple bypass. At five foot eight and 203 pounds, with 32 percent body fat concentrated around his belly, he knows the risks of inaction. But he suspects the drugs are a troubling response to a problem society created. He introduces Hannah, his closest friend, who shared his love of junk food. Hannah died in her mid-forties after developing an opioid addiction, type 2 diabetes, and cancer. Hari believes obesity caused or worsened her chain of illnesses, and her death haunts the entire book.

Hari decides to start taking Ozempic and traces the science behind it. In 1984, Daniel Drucker, a researcher at Massachusetts General Hospital, identified a gut hormone called GLP-1 (glucagon-like peptide-1) and discovered it stimulated insulin production. Separately, John Wilding, a doctor at Hammersmith Hospital in London, found that GLP-1 acts as a natural fullness signal but degrades within minutes. A breakthrough came when John Eng, a biochemist in the Bronx, noticed that venom from the Gila monster, a venomous lizard native to the American Southwest, contained a chemical nearly identical to GLP-1 but lasting hours. Scientists created synthetic versions that remain active for a full week. Approved for diabetics in 2005, these drugs also caused significant weight loss. By 2022, clinical trials showed that semaglutide (marketed as Ozempic for diabetes and Wegovy for obesity) produced an average 15 percent weight loss. Newer drugs yield even greater results, though patients who stop regain roughly two-thirds of the lost weight within a year.

Two days after his first injection, Hari wakes without appetite. Over six months he loses 21 pounds, eventually losing 35 pounds total. His body fat drops from 32 to 22 percent. Yet persistent side effects trouble him: nausea, elevated heart rate, and a deeper emotional unease he cannot explain.

Hari investigates why these drugs became necessary by examining the Western food system's transformation since the late 1970s. His Swiss father grew up eating fresh food in an Alpine village; his Scottish mother embraced processed foods as liberation from manual labor. Journalist Joanna Blythman's investigation of food factories revealed that modern processed food is assembled from thousands of chemical additives in facilities resembling oil refineries. Neuroscientist Paul Kenny's "Cheesecake Park" experiment showed that rats given access to junk food gorged obsessively and, when the junk food was removed, starved rather than return to healthy food.

Hari identifies satiety, the feeling of having had enough, as the link between the food crisis and the drugs. He outlines seven ways processed food undermines satiety, including reduced chewing, blood sugar crashes, lack of protein and fiber, and damage to the gut microbiome. The drugs restore satiety artificially: Michael Lowe, a professor of clinical psychology at Drexel University, calls them "an artificial solution to an artificial problem." Critics argue this approach lets the food industry off the hook, but Hari's friend Judy, a breast cancer survivor, pushes back. When she got cancer, Hari did not tell her to refuse chemotherapy and fight for societal change instead. The house is on fire; douse it with water now, and also fight for better building materials.

Hari details the health harms of obesity, including dramatically elevated risks of diabetes, heart disease, stroke, and cancer, and shows that reversing obesity through bariatric surgery (weight-loss surgery) or these drugs reverses most of those harms. A five-year study of 17,000 adults found Wegovy users were 20 percent less likely to have heart attacks or strokes.

He explains why conventional alternatives mostly fail. Traci Mann, a professor of psychology at the University of Minnesota, reviewed over 2,000 diet studies and found that two years after starting a diet, the average person weighed just two pounds less. The body resists weight loss by slowing metabolism, intensifying hunger, and increasing cravings. Exercise, while enormously beneficial for health, proves similarly limited: Iceland's nationally funded youth sports program produced Europe's most physically active young people, yet Icelandic children remain among the continent's fattest because their increasingly Western diet overwhelmed the exercise benefits. The difficulty of losing weight in the current environment, Hari argues, is one of the strongest arguments for the drugs.

Hari catalogs the drugs' risks against a history of diet drug disasters. In the 1990s, fen-phen, a combination of fenfluramine and phentermine, was prescribed 18 million times before it was found to cause fatal heart defects and pulmonary hypertension, resulting in over $12 billion in settlements. The new drugs are more rigorously tested, but potential risks include increased chances of thyroid cancer and pancreatitis, loss of muscle mass, and malnutrition from extreme appetite suppression.

Scientists discover GLP-1 receptors throughout the brain, meaning the drugs may work by altering brain chemistry rather than acting only on the gut. GLP-1 agonists, drugs that mimic GLP-1, dramatically reduce addiction in animal studies: rats cut alcohol intake by 60 percent, and heroin-seeking dropped by at least half. Some human users report spontaneously losing interest in alcohol, smoking, and compulsive shopping. But if the drugs dampen reward systems, they could cause anhedonia, a blunted capacity for pleasure. European regulators raised a safety signal for suicidal thoughts in 2023, and the question remains unresolved.

Hari identifies five psychological reasons people overeat, from comfort to self-protection. Drawing on research by Vincent Felitti, a physician at Kaiser Permanente, he notes that 60 percent of patients with severe obesity in one program gained their weight after experiencing sexual abuse. The writer Roxane Gay describes a similar dynamic in her memoir Hunger. Ozempic stripped away Hari's own primary coping mechanism, leaving him psychologically vulnerable. He discusses how roughly one in 10 bariatric surgery patients develop "addiction transfers," shifting compulsive behavior from food to alcohol, gambling, or drugs, and how suicide rates increase fourfold after the procedure.

Confronted with the possibility that the drugs' effects may fade over time, Hari begins learning to cook and reconnects with his body through dancing and other physical activities. He examines the drugs' implications for eating disorders, warning they are "rocket fuel" for people determined to starve themselves, and confronts his own motives after a close friend accuses him of prioritizing vanity over health. He investigates the body positivity movement through the story of Shelley Bovey, a pioneering British activist who fought fat stigma but later acknowledged her own obesity was harming her health. Shelley argues that opposing stigma and pursuing health should be "both/and" rather than "either/or."

Hari travels to Japan, the only wealthy country without an obesity crisis, where 3.6 percent of the population is obese. He finds a food culture built on fresh ingredients, small portions, and deliberate education: schools employ nutritionists, all meals are freshly prepared, and children learn about nutrition daily. Japan's 2008 "Metabo Law" requires annual workplace health assessments. Hari learns that the country's food culture was largely invented in living memory, demonstrating that radical change is possible. He catalogs successful interventions from other countries, including Mexico's tax on sugary drinks and Amsterdam's childhood obesity initiative, which cut childhood obesity by 12 percent in four years.

In his conclusion, Hari arrives at three convictions: Society must change the food system so future generations do not need these drugs; individuals must weigh the drugs' risks against obesity's risks in the imperfect present; and urgent measures are needed to protect people with eating disorders. He outlines five possible futures, from a fen-phen-style catastrophe to a cultural awakening that addresses root causes, and predicts the drugs will prove effective but initially limited by cost. He closes with a memory of Hannah, whose death he believes could have been prevented if the crisis had been addressed a generation earlier.